Lonza Group AG
http://www.lonza.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lonza Group AG
The Emergence Of A New Medicinal Platform: mRNA
In the first of a three-part series on the evolution of mRNA manufacturing, this article looks back to before the pandemic, when dogged mRNA researchers and entrepreneurs labored in obscurity pursuing the dream of revolutionizing health care by commandeering the body’s own protein building process to generate quicker, cheaper vaccines and therapeutics. Then the mRNA COVID-19 vaccines stunned the world.
Finance Watch: Sironax, IDRx, OriCell Reveal First VC Mega-Rounds Of August
Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing.
Two Chinese Biotechs Raise $104m To Challenge GSK’s Shingrix
MAXVAX Biotechnology and Beijing Luzhu Biotechnology raise new funds to progress their recombinant herpes zoster vaccine candidates with novel adjuvants, while multiple other ventures in China complete new financings across multiple therapeutic areas and modalities.
Jazz Nabs Novel Narcolepsy Drug From Sumitomo
The Ireland-headquartered firm will advance the candidate into US and EU narcolepsy studies as part of its pipeline diversification project as portfolio products are set to lose their patent exclusivity.
Company Information
- Industry
- Contract Research Organization-CRO
- Diversified
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Services
- Contract Manufacturing Organization
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Algonomics NV
- Capsugel S.A.
- HansaBioMed Life Sciences OÜ
- InterHealth Nutraceuticals, Inc.
- Lonza Group Ltd.
- MODA Technology
- Micro-Macinazione S.A.
- PharmaCell B.V.